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Abstract
We have performed a prospective cohort study to investigate the duration of and risk factors
for prolonged fecal carriage of ESBL-producing Escherichia coli or Klebsiella pneumoniae in
patients with community acquired urinary tract infection caused by these bacteria. From
2009 to 2011, 101 Norwegian patients were recruited. Stool swabs and questionnaires were
collected every three months for one year and at the end of the study in 2012. Information
on antibiotic prescriptions was collected from the Norwegian Prescription Database. Stool
samples were cultured directly on ChromID ESBL agar as well as in an enrichment broth,
and culture positive isolates were examined by blaCTX-M multiplex PCR. Isolates without
blaCTX-M were investigated for alternative ESBL-determinants with a commercial microarray
system. Time to fecal clearance of ESBL producing Enterobacteriaceae was also analysed
using Kaplan-Meier estimates. Uni- and multivariate logistic regression was used to com-
pare groups according to previously described risk factors. The ESBL point prevalence of
fecal carriage were 61% at 4 months, 56% at 7 months, 48% at 10 months, 39% at 13
months, 19% after two years, and 15% after three years or more. We found no correlation
between duration of carriage, comorbidity, antibiotic use or travel to ESBL high-prevalence
countries. Prolonged carriage was associated with E. coli isolates of phylogroup B2 or D.
Importantly, comparative MLST and MLVA analyses of individual paired urine and fecal E.
coli isolates revealed that ESBL production commonly occurred in diverse strains within the
same host. When investigating cross-transmission of ESBL producing bacteria in health
care institutions, this notion should be taken into account.
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Introduction
Extended spectrum β-lactamase producing Enterobacteriaceae (ESBL-E) are an important
cause of nosocomial and community acquired infections [1,2]. The spread of ESBL-E is facili-
tated by their reservoir in the gut of healthy humans and animals, and in water [3]. Certain
clones, such as the epidemic Escherichia coli strain CTX-M 15 ST131, have successfully dissem-
inated internationally [4]. The increasing threat of antibiotic resistance has prompted surveil-
lance of drug-resistant bacteria from stool samples as a tool to track their migration and to
implement infection control measures [5–7].
Several risk factors for the acquisition of intestinal ESBL-E have been described, and they
seem to vary between low- and high-prevalence countries [8–14]. However, there are few stud-
ies regarding the time course of carriage of ESBL-E in the intestine and the factors that may
influence duration of carriage [12,15–18]. Knowledge about carriage duration is important for
implementation of adequate infection control measures, and essential in the construction of
mathematical models in our understanding of the epidemiology of ESBL-E dissemination.
Previous studies on clinical patients conclude that fecal carriage seems to be common sev-
eral months after an infection with ESBL-E, and that ESBL-E negative stool samples occur
intermittently during colonisation. However, they identify different risk factors for prolonged
carriage, such as urinary catheter use [16], immobility [17], infection with E. coli strains
belonging to phylogroup B2 (which includes ST131) [15,18] and CTX-M group 1 enzymes
[15].
We have previously shown that travel to high-prevalence countries, antibiotic use, diabetes
and fresh-water swimming are independent risk factors for UTI caused by ESBL-E [8]. In this
prospective cohort study of the same patients, we examined the duration of fecal carriage of
ESBL-E, potential risk factors for prolonged carriage and the clonal relatedness between paired
ESBL-producing E. coli urinary and fecal strains.
Ethics statement
The study was approved by the Regional Committee for Medical and Health Research Ethics
December 11th 2008 (reference number: 2009/2037 BS-08901b). It is registered in the Clinical-
Trials.gov registration system, registration ID NCT01838213 in 2013. As this is an epidemio-
logical observational study, registration as a clinical trial was not considered as necessary at the
beginning of the project in 2009, but was done in April 2013. The authors confirm that all trials
on going and related to this project are registered. The included population has also been part
of two previously published case control studies by Søraas et al on risk factors for urinary tract
infections caused by ESBL-E [8], and on the effects of pivmecillinam treatment of these infec-
tions [19], available as supplementary files S7 and S8. The complete and detailed study proto-
col as approved by the ethics committee before the study began is available as supporting
information S5 and S6. An addition to the protocol was submitted and approved by the ethics




Vestre Viken Hospital Trust is situated in a mixed urban and suburban region in the South-
Eastern part of Norway, and has a catchment area of 475.000 inhabitants. Our Department of
Medical Microbiology analyses samples from both in- and out-patients. Inclusion of patients
started in March 2009, and the last samples were collected in August 2012.
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Data collection
This prospective cohort study included patients above 18 years, with a urine culture yielding
>10,000 CFU/ml ESBL producing E. coli or K. pneumoniae. Exclusion criteria were as follows:
1) residency in Norway for less than one year, 2) healthcare associated urinary tract infection,
3) inability to answer questionnaires, and 4) previous ESBL-E infection. All participants gave a
written consent of participation.
Patients were recruited between March 10th 2009 and March 21st 2011. At inclusion, the
patients were asked to deliver a fecal sample and undergo a structured interview regarding pos-
sible risk factors for ESBL positive UTI [8]. They were then followed prospectively with new
fecal samples and questionnaires every 3 months for one year. In May 2012, all participants
were asked to deliver a new stool sample and questionnaire, regardless of their time since
inclusion (Fig 1). The questionnaires concerned occurrence of new urinary tract infections,
international travel or residency, antibiotic use, and foreign visitors in the household. To
secure optimal sampling, the participants were given instructions to obtain the fecal sample
from used toilet paper by use of cotton swabs transported on Amies medium and ensure that
visible fecal material was deposited on the swab.
Purchasing dates, types and amount of antibiotic drugs sold to the patients during the study
period were obtained from The Norwegian Prescription Database, and antibiotic use during
hospitalization was recorded from the patients’ medical records. Only systemic drugs with
ATC-codes in group J were included, including antimycotics but excluding methenamine,
antiviral drugs and vaccines. As a measurement for antibiotic consumption, defined daily
doses (DDDs) for each drug is a useful tool [20]. The measurement unit DDD is defined as the
assumed average maintenance dose per day for a drug used for its main indication in adults.
Laboratory methods
Identification and ESBL-detection in urine isolates. Urine cultivation, bacterial identifi-
cation and antibiotic susceptibility testing were performed using ChromID ESBL agar and the
VITEK-2 system (both from bioMérieux, Marcy l’Etoile, France). For antimicrobial suscepti-
bility interpretations we used EUCAST breakpoints (http://www.eucast.org), and for ESBL/
AmpC-confirmation the E-test system (AB-Biodisk, BioMérieux). ESBL genotype analysis was
performed using PCR for blaCTX-M detection and group assignment as described [21]. Urine
isolates negative for blaCTX-M were analysed using conventional blaTEM and blaSHV PCR and
sequencing [22].
Identification and ESBL-detection in fecal isolates. The fecal samples were cultured
directly on lactose (growth control) and selective chrome agar, and also in selective brain heart
infusion enrichment broth containing cefotaxime 2.5 g/L, with sub cultivation on chrome
agar. Isolates with a colour indicating E. coli or Klebsiella sp. were included for further analysis.
Oxidase negative isolates with atypical colours were identified by VITEK-2. All fecal E. coli and
Klebsiella isolates with an ESBL or AmpC phenotype were investigated for blaCTX-M with the
same method as the urine isolates.
Species identification of the blaCTX-M negative isolates was confirmed by MALDI-TOF
(Bruker Daltonics, Germany). Confirmed ESBL or AmpC phenotypes were analysed by micro-
array Check-MDR CT101 (Check-Points B.V., Wageningen, the Netherlands) targeting bla-
TEM, blaSHV, blaNDM, blaKPC, as well as the following plasmid mediated AmpC variants: CMY,
DHA, FOX, ACC, ACT, MIR and MOX.
MLVA, MLST-typing and phylogroup assignment of E. coli isolates. Clonal relatedness
between fecal and urinary ESBL-producing E. coli was examined by a multilocus variable num-
ber of tandem repeats assay (MLVA) protocol originally described by Lindstedt et al and
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Fig 1. Flow diagram of study patient inclusion.
doi:10.1371/journal.pone.0173510.g001
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modified by Løbersli et al [23,24]. Briefly, PCR-products were subjected to capillary electro-
phoresis, and each peak was identified according to colour and size by GeneMapper software
(Applied Biosystems, Foster City, CA, USA). Allele numbers were assigned according to frag-
ment sizes as previously described [24]. Character values were entered into BioNumerics
(Applied Maths, Saint-Martens-Letem, Belgium), and dendrograms were constructed using
categorical coefficients and the Ward algorithm. A standard minimum spanning tree was gen-
erated using categorical coefficients together with the single and double locus variance priority
rules. Whole genome sequencing by Illumina technology (Illumina, San-Diego, USA) generat-
ing 150 base pairs paired-end reads was performed on all E. coli urine isolates. Identification of
eight housekeeping genes with corresponding alleles and sequence types (STs) were deter-
mined by using the database at Center for Genomic Epidemiology [25,26]. To establish
whether the urine isolates belonged to phylogroup B2 or D, we conducted BLAST analysis
(www.blast.ncbi.nlm.nih.gov) seeking alignment with chuA [27].
Statistical analysis and risk factor definitions
Sample size was calculated to fit the previously published case-control study [8]. Point preva-
lence rates were calculated for each three-month period. Carriage survival was estimated in a
Kaplan-Meier curve. As many patients with negative samples later became positive in new
samples, we found it appropriate to define ESBL-E clearance as two consecutive negative sam-
ples, and to present an estimate where the event end-point is set to occur at the first negative
sample if the following sample also is negative. For further risk factor analysis, we used carriage
at 13 months after inclusion as the dependent variable in uni- and multivariable analyses. Uni-
variate analyses were performed using Student’s t test or Pearson’s chi-square test when appro-
priate. Multivariate analyses were preceded by estimation of correlation between risk factors in
a multiple logistic regression model. To reveal significant risk factors for persisting ESBL-E
carriage at 13 months, we conducted backwards elimination of variables, starting by including
previously described risk factors related to microbe- and patient characteristics. There was
only one variable significantly associated with prolonged carriage. Thus, an exploratory model
of hypothetical risk factors is presented [28]. The association between potential risk factors
and carriage duration was quantified by odds ratio (OR) with 95% confidence interval (CI). A
P-value < = 0.05 was considered significant. The continuous variables have been dichoto-
mized, but the main results were robust to alternative operationalizations. Statistical analyses
were conducted using PASW statistics software, version 21.0 (IBM SPSS, IL, USA) and Stata
Statistical Software release 13 (StataCorp, TX, USA).
Results
Approximately 28,000 urine samples from 15,000 unique patients were submitted to our
department during the inclusion period. A total of 359 (1.3%) samples yielded ESBL positive
E. coli or K. pneumoniae. After exclusion, 172 subjects with ESBL-E UTI were invited to partic-
ipate, and 101 cases (56%; E. coli (n = 96) and K. pneumoniae (n = 5)) were included; women
(n = 89) and men (n = 12), with a median age of 55 years (range 18–95). The mean age was 2.8
years higher for participants than for non-participants, otherwise no statistically significant
difference was found between groups [8]. Two patients died during the study, and six others
were lost to follow-up. All samples from these patients were excluded in the statistical analyses.
Within the first 13 months of inclusion, eleven patients report to have received antibiotic treat-
ment in hospital. In all cases, this treatment took place within the first three months after
inclusion. We asked for 595 fecal samples in total, and received 519 (87%). Of these, 247 sam-
ples (48%) contained one or more morphologically distinct colonies of ESBL-E. Molecular
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detection of bla was performed on 267 morphologically distinct fecal isolates from 77 patients
of which 237 (89%) were E. coli. The enrichment broth yielded only two additional positive
samples compared with direct culture, of which one was an AmpC-phenotype E. coli. The fol-
low-up time varied from 12 to 41 months, with an average of 27 months. Ninety-three patients
were followed for one year. The follow-up time was dictated by the time of inclusion. Hence,
44 patients were eligible for two years follow up, from which we received final samples from 43
(98%). 13 patients were eligible for three years follow up, and we received samples from all of
these. A comparison of the two-year and three-year groups to the total cohort is presented in
Table 1.
ESBL genotypes
In the 101 urine isolates blaCTX-M group 1, group 9 and ESBL-type blaSHV were present in 66
(65%), 30 (30%) and in five (5%) of the urinary isolates respectively. The ESBL-genotype pro-
portions were quite similar in fecal isolates; 61%, 35% and 4%. We also detected one blaKPC-
positive, one blaDHA and one blaCMY-II−/blaSHV−positive strain.
Travel
Of the 93 patients who completed the study, 73% (n = 68) travelled outside of the Nordic coun-
tries during the study period. The most frequent destinations were Spain (n = 46), Africa and/
or Asia (n = 17), and America (n = 6). One patient was permanently living in India. The partic-
ipants had between zero and 343 travel days (mean 14 days).
Antibiotic use
Excluding the first two weeks after the UTI diagnosis, a total of 74 patients (80%) received anti-
biotics during the study period. The most commonly used drug was pivmecillinam followed
by nitrofurantoin. There were 16 reported cases of antibiotic treatment in hospitals. According
to the Norwegian Prescription Database, a total number of 3,973 defined daily doses (DDDs)
of antibiotics were purchased by the patients throughout the study, with a range of zero to 732
(mean 54, median 23) DDDs per patient for a total number of patient days of 76,265. This
equals 52 DDDs/1,000 patient days. The majority of the consumed antibiotics were those com-
monly used for the treatment of UTI (data in S1 Fig. Antibiotic consumption). On-going anti-
biotic therapy, or antibiotic use within 5, 10, 30 or 90 days prior to sampling did not correlate
with the sample being positive for ESBL-E.
Duration of carriage
The observed prevalence carriage rate was 53/87 (61%) at 4 months, 48/86 (56%) at 7 months,
40/84 (48%) at 10 months, 33/84 (39%) at 13 months, 8/43 (19%) after two years or more, and
2/13 (15%) after three years or more; 13 of 93 patients (14%) with negative samples became
positive again in later samples. In Fig 2, the ESBL-E clearance rate is illustrated in a Kaplan-
Meier survival curve (Fig 2). In this analysis, 50% of the participants are negative at 12 months.
Only three patients (3%) became positive after two or more consecutive negative samples. In
these cases, the last isolates were a new ESBL-producing species (n = 1), or had a different E.
coli MLVA genotype (n = 2). All three had travelled to high-endemic countries after the second
negative sample but before the new positive sample.
Phylogroup, as defined by presence of chuA was the only variable significantly associated
with prolonged carriage. An exploratory model of hypothetical risk factors is presented
(Table 2).
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MLVA-analysis of selected ESBL-producing urinary and fecal E. coli isolates. All
strains from patients who were ESBL-E carriers for more than 13 months (n = 35), were
selected for MLVA. These long-term carriers delivered 168 E. coli fecal isolates in total (range
1–7, median 5). Among the E. coli urine isolates (n = 97) of all participants and fecal isolates
(n = 168) from the 35 long-term carriers, we identified 80 distinct MLVA-types; three large
Table 1. Comparison of participants according to follow-up time.










Male sex 12 (13%) 6 (10%) 3 (23%)




Chronic UTI 20 (21.5%) 9 (20.5%) 3 (23.1%)
Antibiotics* 66 (71%) 31 (70.5%) 8 (61.5%)
Travel to Asia, Africa or Middle-East within first 15
months after UTI
20 (21.5%) 10 (22.7%) 5 (38.5%)




E. coli phylogroup B2/D in urine 65 (70%) 33 (75%) 10 (77%)
* = Any antibiotic received between 14 days and 13 months after positive urinary sample.
doi:10.1371/journal.pone.0173510.t001
Fig 2. Kaplan-Meier survival plot. Fecal ESBL-E clearance is defined to occur at the first negative sample if the
following sample also is negative.
doi:10.1371/journal.pone.0173510.g002
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clusters containing 20, 27 and 31 isolates respectively, 23 clusters containing between three
and 12 isolates, 10 clusters with two isolates, and 44 singletons (Fig 3). Both fecal and urine iso-
lates are present in 24 of the clusters. The three largest clusters and twelve of the isolates closely
related to them, shared a MLVA profile that corresponds to ST131 (S1 Data) [30].
We identified 35 different STs and 51 different MLVA profiles in the urine isolates. The
largest group contained 27 urine strains of ST131. The second largest group contained 13 iso-
lates that belonged to ST38. The other STs were present in four strains or less. Correlation of
MLVA profiles and STs is illustrated in Fig 4 and listed in S1 Data.
Of the 35 long-term carriers, only two participants (6%) had the same MLVA-type in all
samples. Two different types were present in 15 patients (43%), while there were three, four
and five types in 12 (34%), four (11%) and three (9%) patients respectively. Ninety-eight of 168
positive fecal samples (58%) contained either a different ESBL producing species (5%, n = 8)
or an E. coli with a different MLVA-type than the urinary isolate (54%, n = 90). Fifteen patients
(45%) had the same E.coli MLVA-type in urine as in the first fecal sample. Changes in ß-lacta-
mases within the same MLVA-type in the same patient occurred in four cases (11%). Changes
in species, β-lactamases and MLVA-types in each patient are illustrated in Fig 5.
Discussion
We have examined fecal ESBL-E carriage duration in patients with UTI caused by ESBL-pro-
ducing E. coli or K. pneumoniae. Ninety-three patients were followed for one year, 44 patients
for two years, and 13 patients for three years or more. We recorded known risk factors for
ESBL-carriage and characterized the ESBL-producing E. coli isolates by MLVA.
Patient compliance in follow-up was successful, as 87% of requested fecal samples were
delivered. We found that 44% were still ESBL-E carriers after one year by using survival analy-
sis defining clearance as two consecutive negative samples. This may be an overestimation of
ESBL-E clearance time, as the actual elimination of the ESBL-E carriage is unlikely to fall upon
the exact date of the first negative sample. One could argue that the end-point should be set
between the last positive sample and the first negative sample. On the other hand, one could
also argue that the end-point should be set at the second negative sample, because a second
sample is needed to confirm negativity in a clinical setting. The ESBL-E elimination rate esti-
mate curve flattens in the two last years of the study, because we have set the end-point to
occur at the first of two consecutive negative samples. Consequently, the latest possible event
Table 2. Multiple logistic regression model of potential risk factors for ESBL-E carriage 13 months after urinary tract infection.
Univariate analysis Multivariate analysis
Variable ESBL-positive (n = 44) ESBL-negative (n = 39) OR 95% CI P OR 95% CI P
Age > 65 years 18 13 1.4 0.59–3.5 0.426 1.8 0.60–5.4 0.294
Male sex 5 5 0.9 0.24–3.4 0.872 0.85 0.18–3.9 0.833
Chronic urinary tract infection 11 9 1.2 0.42–3.2 0.788 1.0 0.32–3.3 0.957
Charlson score[29] >2 7 4 1.7 0.46–6.3 0.426 1.7 0.39–7.2 0.480
Number of household members >3 8 5 1.6 0.46–5.2 0.474 1.5 0.37–5.8 0.594
E. coli phylogroup B2 or D in urine 37 24 3.3 1.2–9.3 0.023 3.8 1.2–12.6 0.027
CTX-M group 1 in urine isolate 26 28 0.62 0.25–1.5 0.299 0.70 0.26–1.9 0.492
Antibiotics* 32 31 0.77 0.27–2.1 0.614 0.97 0.32–3.0 0.958
Travel to Asia, Africa or Middle-East 10 10 0.92 0.32–2.4 0.807 0.778 0.25–2.4 0.661
Clearance is defined as two consecutive negative samples. OR = odds ratio for ESBL persistence, CI = confidence interval.
* Any antibiotic received between 14 days and 13 months after positive urinary sample.
doi:10.1371/journal.pone.0173510.t002
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occurs at 13 months. When interpreting the curve, it is also important to remember that the
interval between the 13-months sample and the last sample varies considerably between the
participants. Simple point prevalence analysis with clearance defined as only one negative sam-
ple, reveals slightly lower positivity rates, as some patients delivered transient negative samples.
Fig 3. Minimum spanning tree of E. coli urine isolates (97 isolates from 95 patients) and fecal isolates
(168 isolates from 35 patients). Urine isolates are marked with red colour, fecal isolates with green colour.
Short, fat lines between two nodes signify that the strains in each node have a different band number in only
one locus. Long, thin lines between two nodes signify different band numbers in more than one locus. ST131
strains are marked with #.
doi:10.1371/journal.pone.0173510.g003
ESBL fecal carriage after urinary tract infection
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Consequently, we recommend that at least two negative samples are obtained to verify ESBL-E
clearance. To investigate the ideal time interval between these samples was beyond the scope
of this study.
Our clearance rates are in accordance with previous studies from Sweden, Slovenia and
France [15,17,31,32]. Lack of detection of ESBL-E does not confirm absence of ESBL-E, but
the risk of further spread can probably be regarded as low. Self-sampling may influence the
sensitivity of microbiological tests, but in this study bacterial growth was obtained from all but
one sample, in which case a repeated sample was obtained. Contrary to other studies [33], cul-
ture in selective enrichment broth did not give a significantly higher yield of ESBL-E. This
Fig 4. Minimum spanning tree of E. coli urine isolates (97 isolates from 95 patients) represented as
circles with STs labelled and represented with different colours. Short, fat lines between two nodes signify
that the strains in each node have a different band number in only one locus. Long, thin lines between two nodes
signify different band numbers in more than one locus. Each ST is represented with a distinct colour.
doi:10.1371/journal.pone.0173510.g004
ESBL fecal carriage after urinary tract infection
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Fig 5. Species, E. coli MLVA types and ß-lactamase enzymes in long-term fecal carriers (n = 35). Each ß-lactamase enzyme is
marked with a distinct colour: grey square = CTX-M group 1, green square = CTX-M group 9, pink square. = SHV, blue square. = KPC,
yellow square = several different ß-lactamases. Variation in E. coli MLVA-type is marked by separate symbols:● = E. coli first MLVA-
type,  = E. coli second MLVA-type,◘ = E. coli third MLVA-type,◙ = E. coli fourth MLVA-type,■ = E. coli fifth MLVA-type. Species
other than E. coli are marked by triangles:▲ = K. pneumoniae,▼ = Enterobacteriaceae other than E. coli or K. pneumonia. ns = no
sample, - = no ESBL-producing isolate found, miss = lost sample.
doi:10.1371/journal.pone.0173510.g005
ESBL fecal carriage after urinary tract infection
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could be due to differences in media composition, lack of vancomycin to inhibit growth of
Enterococci, and the higher concentration of cefotaxime in our broth.
Apart from the long duration of ESBL-E carriage, our most important finding is the high
genetic diversity among ESBL-producing E. coli strains within the same individual. Changes in
MLVA-type occurred during long term fecal carriage in 89% of the patients. A patient’s fecal
MLVA-type differed from the urinary type in 54% of the samples. There is less concordance
between urine strains and fecal strains than shown in previous studies of patients with non-
ESBL E. coli UTI [34], but the differences may be due to different typing methods. The seven
loci MLVA protocol which we have used, gives a differentiation similar to pulsed-field gel elec-
trophoresis [23,35]. In the MLVA minimum spanning tree, we observe a nice clustering of the
dominating STs (ST131 and ST38), as previously shown by others [30].
The ESBL encoding elements are most often situated on plasmids that are horizontally
transmitted between bacteria. Thus, it is likely that spread to new strains and species within
the same patient increases during prolonged carriage. Comparative studies of ESBL-E within
households and in long term care institutions also show genetic diversity in carriage strains
[14,35,36]. For the majority of our patients, the CTX-M group is the same even if the MLVA-
type changes. This observation supports the notion of horizontal gene transfer rather than the
acquisition of a new ESBL-producing strain. We performed MLVA-analysis of morphologi-
cally distinct colonies from each positive fecal sample, but only on one isolate of each morpho-
type. This approach does not allow detection of different ESBL-producing strains with the
same morphotype at individual time points. The observed change in MLVA-types over time
may be caused by an alteration in the relative dominance between the strains. Furthermore,
the initial strain may have evolved sufficiently to be perceived as a new genotype over time.
The observed genetic diversity in the fecal isolates has potential implications in an outbreak
setting, where attempts to track the spread of individual clones have been customary [6,31,37].
It is relevant to question if such tracking is a reasonable approach, based on the observed diver-
sity among ESBL producing fecal E. coli strains in individual samples. This diversity has been
demonstrated by different methods [15,31,34,38]. A recent study from a high-endemic setting,
using whole genome sequencing on 16 E. coli colonies from each of seven ESBL-positive fecal
samples, disclosed a substantial genetic diversity [38]. Similar genetic variations in fecal E. coli
isolates have been observed from patients with UTI in an ESBL-E low-prevalence setting [34].
During an outbreak investigation, the index patient may thus carry a diversity of ESBL produc-
ing E. coli strains. Consequently, cross-transfer should not be ruled out, even if the microbe
fingerprints from randomly selected fecal E. coli colonies differ between patients.
We found a significant association between phylogroups B2/D and prolonged carriage as
previously shown (15). Neither MLVA-types, nor single STs, nor any particular CTX-M
groups were correlated to prolonged carriage. Our major contributors to phylogroups B2/D
are ST131 (n = 33) and ST38 (n = 13). In a previous study, ST131 has been associated with pro-
longed carriage in a cohort of long term health care facility residents [18], while other studies,
like the present, do not find this correlation [15,17]. Our observation support the notion that
also other strains than ST131 have potential to colonise the human intestine for a long time.
The studies that do not find significant correlation between ST131 and prolonged carriage
include samples containing other B2/D strains that could be equally persistent.
The observed differences in risk factors for prolonged carriage in previous studies may be
related to several factors. The patient populations are somewhat different, as the other studies
mainly included hospitalized patients, there were more men, and the average age was slightly
higher. The patients suffered from different conditions; we only included patients with com-
munity acquired UTI, while the others also included patients with ESBL-producing bacteria in
other clinical specimens. There are also variations in sample size.
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In accordance with previous carriage studies [12,15,17], we did not find any correlation
between antibiotic use and prolonged ESBL colonisation within the study cohort, neither
regarding the antibiotic type or amount, nor the timing between antibiotic treatment and fecal
samples (S3 Data). However, there are several studies observing association between previous
antibiotic use and infection with ESBL-E. The average antibiotic consumption among the
study participants was twice as high as in an age- and sex matched cohort from the same
region in 2011, i.e. 52.1 DDDs/1,000 patient days in the study group versus 25.5 DDDs/1,000
inhabitants/day in the population group [39]. As the study cohort is selected among patients
with UTI, and 12% of participants suffer from recurrent UTI, this is not surprising. Antibiotics
create a selective pressure that favours resistant microbes. The ESBL-carrying plasmids also
often contain other resistance genes. Thus, antibiotics which do not directly select for ESBL
may provide a selective advantage for genetically linked resistance determinants on the same
plasmid. Lack of significant correlation between prolonged carriage and the use of antibiotics
may well be a type II error due to our limited sample size. Other presumed, but rarely occur-
ring risk factors included in the model, such as more than three household members, male sex
and high co-morbidity score, may also be a subject to type II errors.
Surprisingly, there was no association between prolonged carriage and travel to high-
endemic countries. Our hypothesis was that travel to high-endemic areas would be a risk factor
for acquiring new ESBL-E strains, thereby decreasing the odds of being ESBL-E negative in
subsequent samples. We expected that the variety of strains would be greater in the travellers
than in others. However, as we have discussed above, the variation in fecal genotypes is large
regardless of travel. A different study design would be necessary to clarify whether the
observed diversity is caused by plasmid transfer between strains, genomic evolution of strains
over time or parallel infection with different strains.
Conclusion
We observed an overall ESBL-E fecal clearance rate of 56% one year after a UTI caused by an
ESBL-producing E. coli or K. pneumoniae. UTI caused by E. coli phylogroup B2 or D strains
are associated with prolonged fecal ESBL-E carriage. A single negative sample is not sufficient
to assume ESBL-clearance. ESBL production can be detected in several fecal Enterobacteriaceae
species, and in diverse E. coli genotypes within the same host. When investigating cross-trans-
mission of ESBL producing bacteria in health care institutions, this notion should be taken
into account.
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